{"id":49298,"date":"2021-08-31T05:05:25","date_gmt":"2021-08-31T05:05:25","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=78004"},"modified":"2021-08-31T05:05:25","modified_gmt":"2021-08-31T05:05:25","slug":"junshi-biosciences-announces-2021-interim-financial-results-and-provides-corporate-updates","status":"publish","type":"post","link":"https:\/\/malaysiantribune.com\/junshi-biosciences-announces-2021-interim-financial-results-and-provides-corporate-updates\/","title":{"rendered":"Junshi Biosciences Announces 2021 Interim Financial Results and Provides Corporate Updates"},"content":{"rendered":"
SHANGHAI, China, Aug. 31, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the six months ended June 30, 2021 and provided corporate updates.<\/p>\n
First Half 2021 Financial Highlights<\/strong><\/p>\n Business Highlights<\/strong> We expanded our product pipeline through forming joint ventures with our partners and other means. Apart from developing drug candidates on our own technology platforms, we also actively collaborated with outstanding domestic and overseas biotechnology companies to further expand our product pipeline, deploy next-generation innovative drug technology platforms and augment drug combination therapies.<\/p>\n In June 2021, we issued an aggregate of 36,549,200 new H shares at the placing price of HK$70.18 per H share to no less than six placees (the \u201cPlacing\u201d). The net proceeds from the Placing are approximately RMB 2,106 million. The proceeds from the Placing are intended for increased R&D, expansion of the commercialization team, domestic and overseas investments, mergers and acquisitions, business development, and general corporate purposes.<\/p>\n About Junshi Biosciences<\/strong> Contact Information<\/strong><\/p>\n IR Team:<\/strong> Solebury Trout<\/strong>\n
\nDuring the six months ended June 30, 2021, we have achieved significant progress with respect to our product commercialization, clinical trials and pipeline expansion. Our innovative R&D field has expanded from monoclonal antibodies to the development of more drug modalities, including small molecules, polypeptides, antibody drug conjugates (ADCs), bi-specific or multi-specific antibodies and nucleic acid drugs, as well as the exploration of next-generation innovative therapies for cancer and autoimmune diseases. Our drug candidates cover 5 major therapeutic categories including malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases, and infectious diseases. Currently, we have 2 commercialized products (toripalimab and etesevimab), one filed NDA (adalimumab), 16 drug candidates under clinical trials (among which senaparib, ongericimab and bevacizumab were in Phase III trials) and 25 drug candidates in pre-clinical drug development.<\/p>\n\n
\n
\nFounded in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The Company has established a diversified R & D pipeline comprising 44 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for an anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology of Chinese Academy of Science and Eli Lilly to co-develop JS016 (etesevimab), China\u2019s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has obtained the EUA in more than 12 countries and regions worldwide. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http:\/\/junshipharma.com<\/a>.<\/p>\n
\nJunshi Biosciences<\/strong>
\ninfo@junshipharma.com<\/u><\/a>
\n+86 021-2250 0300<\/p>\n
\nBob Ai
\nbai@soleburytrout.com<\/u><\/a>
\n+1 646-389-6658<\/p>\n